诉讼案件 - 诉讼针对Zenas BioPharma公司(NASDAQ: ZBIO)在2024年9月IPO期间发行的证券 [1] - 诉讼代表在特定期间购买或获得Zenas BioPharma证券的股东 [1] 指控内容 - 指控公司在诉讼期间发布了重大虚假和/或误导性陈述 [2] - 指控公司未能披露其夸大现有现金和IPO预期净收益可支持运营的时间 [2] - 指控公司公开声明存在重大虚假和误导性且准备疏忽 [2] 诉讼程序 - 股东需在2025年6月16日前登记参与集体诉讼 [3] - 登记股东将获得案件生命周期内的状态更新 [3] - 申请成为首席原告的截止日期为2025年6月16日 [3] 律师事务所 - Gross Law Firm是一家全国知名的集体诉讼律师事务所 [4] - 该律所专注于保护因欺骗、欺诈和非法商业行为受损的投资者权益 [4] - 律所致力于确保公司遵守负责任的商业行为和良好企业公民准则 [4]

SAN DIEGO, June 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the "IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Ze ...

诉讼案件概述 - 罗森律师事务所提醒Zenas BioPharma公司(NASDAQ: ZBIO)在2024年9月IPO时购买证券的投资者注意2025年6月16日的首席原告截止日期 [1] - 诉讼指控Zenas BioPharma在注册声明中存在虚假或误导性陈述 未披露公司夸大现有现金和IPO预期净收益可支撑运营的时间 [5] - 当真实信息进入市场后 投资者遭受损失 [5] 投资者参与方式 - 投资者可通过罗森律师事务所网站或电话加入集体诉讼 无需支付自付费用 [2][3] - 首席原告需在2025年6月16日前向法院提出申请 首席原告代表其他集体成员指导诉讼 [3] - 投资者可选择自行聘请律师或保持缺席集体成员身份 未来获得赔偿不取决于是否担任首席原告 [7] 律师事务所背景 - 罗森律师事务所在证券集体诉讼领域具有领先地位 2017年ISS证券集体诉讼服务排名第一 [4] - 2019年为投资者追回4.38亿美元 累计追回数亿美元 [4] - 创始合伙人Laurence Rosen被law360评为原告律师界泰斗 多名律师获得Lawdragon和Super Lawyers认可 [4]

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captio ...

NEW YORK, June 6, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Zenas BioPharma's September 2024 initial public offering ("IPO" or the "Offering"), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.So Wh ...

Zenas BioPharma (ZBIO) 2025 Conference June 05, 2025 01:25 PM ET Speaker0 Right. Welcome everyone to Jefferies twenty twenty five Global Healthcare Conference. My name is Roger Song, one of the senior analysts cover semi cap biotech in The US. It is my great pressure to introduce our next printing company, Dennis, BioPharma. And now we have the CEO, Lonnie Mota. And then he will give us some copy presentation, and then we're gonna have some q and a toward the end. Welcome, Lonnie. Speaker1 That sounds great ...

NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=151564&from=4CLASS PERIOD: This lawsuit ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zenas BioPharma, Inc. ("Zenas BioPharma" or the "Company") (NASDAQ: ZBIO) investors of a class action representing investors that bought securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with its initial public offering (“IPO”) held on or around September 13, 2024, and suffered damages as a re ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=150967&from=3 CLASS PERIOD: Thi ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas’ registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click ...